HDM2024
/ Huadong Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 12, 2026
Huadong Medicine…announced that HDM2024, a Category 1 innovative bispecific antibody-drug conjugate (Bs-ADC), has received FDA clearance to initiate a Phase I clinical trial for the treatment of advanced solid tumors
(flcube.com)
- "The first-in-class candidate simultaneously targets EGFR (HER1) and HER3, delivering a DNA topoisomerase I inhibitor payload via a cleavable linker to block proliferative signaling while exerting direct cytotoxic antitumor effects."
New P1 trial • Solid Tumor
1 to 1
Of
1
Go to page
1